Nano Science and Technology Institute - NSTI  
Nano Science and Technology Institute   Home | Subscribe | Site Map  
  ABOUT | COURSES | EVENTS | PUBLICATIONS | LEADERSHIP | OUTREACH | NEWS | PRESS | JOBS | Nanotechnology Solutions
px
px fade_top
Publications
Nanotech 2008 CDROM
Nanotech 2007 CDROM
Nanotech 2006 CDROM
Nanotech 2005 CDROM
Nanotech 2004 CDROM
3 CDROM Special Offer
Nanotech 2008 Vol. 1
Nanotech 2008 Vol. 2
Nanotech 2008 Vol. 3
Nanotech 2007 Vol. 1
Nanotech 2007 Vol. 2
Nanotech 2007 Vol. 3
Nanotech 2007 Vol. 4
Nanotech 2006 Vol. 1
Nanotech 2006 Vol. 2
Nanotech 2006 Vol. 3
Nanotech 2005 Vol. 1
Nanotech 2005 Vol. 2
Nanotech 2005 Vol. 3
WCM 2005
Nanotech 2004 Vol. 1
Nanotech 2004 Vol. 2
Nanotech 2004 Vol. 3
Nanotech 2003 Vol. 1
Nanotech 2003 Vol. 2
Nanotech 2003 Vol. 3
Nanotech 2002 Vol. 1
Nanotech 2002 Vol. 2
Nanotech 2001 Vol. 1
Nanotech 2001 Vol. 2
MSM 2000
MSM 99
MSM 98
Index of Authors
Index of Keywords
Index of Affiliations
Library Request Form
Shopping Cart
Order Form
 
Publications Publications
Nanotech 2005 Vol. 1
p
 
Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, Volume 1
Nanotech 2005 Vol. 1
Technical Proceedings of the 2005 NSTI Nanotechnology Conference and Trade Show, Volume 1
 
Chapter 1: Nanotechnology for Cancer
 

Maxitarg-A Novel Targeting Approach for Hepatic Cancer

Authors:G.S. Sonavane and P.V. Devarajan
Affilation:Mumbai University Institute of Chemical Technology, IN
Pages:11 - 14
Keywords:MAXITARG, nanoparticle, hepatic cancer
Abstract:The efficacy of current cancer chemotherapy is mainly limited by toxicity associated with the systemic spread of anticancer drugs to normal tissues. Enhancing selectivity or maximizing targeting towards cancer cells would be important approach to decrease toxicity while enhancing efficacy. The present approach, ‘MAXITARG’ to maximize the targeting of drugs deals with the use of a novel-targeting agent with high affinity for hepatocellular carcinoma cells. Doxorubicin is widely used for various solid tumors and melanomas including hepatocellular carcinoma. Limitations of doxorubicin delivery include dose limited cardiotoxicity and myelosuppression. The result of this is often a narrow therapeutic index, due to high levels of toxicity to healthy tissues. ‘MAXITARG’ deals with the use of alginic acid-sodium alginate nanoparticles (ANP) with the novel-targeting agent for the therapy of hepatic cancer. The aim of the present study is to use the ‘MAXITARG’ approach to maximize delivery of doxorubicin to hepatic carcinoma cells. The results suggested the promise of developed ‘MAXITARG’ as a suitable approach for hepatic cancer. The technology could be extrapolated to other category of drugs for liver targeting.
ISBN:0-9767985-0-6
Pages:844
Hardcopy:$165.00
 
Order:Mail/Fax Form
Special:3 CD Set — 15% off with Free Shipping
Up
nanoPRwire™
nanoPRwire
News Headlines
nano World news
 
 
 
 
px
© Nano Science and Technology Institute     About NSTI | Terms of Use | Privacy Policy | Contact